| Title | High dose methotrexate therapy of childhood acute lymphoblastic leukaemia: incidence of nephrotoxicity and glomerular dysfunction | |
| Authors | Aggeliki Theodoridou, Fani Athanassiadou-Piperopoulou, Theodotis Papageorgiou, Magdalini Gatzola-Karaveli and Areti Makedou-Hitoglou
2nd Pediatric Clinic of Aristotle University of Thessaloniki, Department of Pediatric Hematology and Oncology, AHEPA Hospital |
|
| Citation | Theodoridou, A., Athanassiadou-Piperopoulou, F., Papageorgiou, Th., Gatzola-Karaveli, M., Makedou-Hitoglou, A.: High dose methotrexate therapy of childhood acute lymphoblastic leukaemia: incidence of nephrotoxicity and glomerular dysfunction, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 332-334 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Methotrexate, high dose methotrexate, acute lymphoblastic leukemia, nephrotoxicity, glomerular function. | |
| Other Terms | review article | |
| Summary | High-dose methotrexate (HDMTX) is used in the treatment of children with acute lymphoblastic leukemia (ALL) during the consolidation phase. Renal dysfunction is considered among the side effects following MTX therapy. The aim of the study was to evaluate the incidence of nephrotoxicity due to HDMTX in children with ALL and to clarify whether glomerular dysfunction is involved. In the sixteen patients included in the study, no serious renal dysfunction occurred. The increase in serum creatinine (sCr) 1 and 2 days after the start of HDMTX infusion was mild and transient and sCr returned to base-line values 7 days after administration of the drug. The mean value of GFR at the end of HDMTX administration decreased significantly compared to the prior to the infusion value (118.15±32.59 vs. 142.93±23.7, p<0.01), but still remained within normal range. No relation was observed between sMTX concentrations and GFR. A de- creased GFR was not associated with an increase in sMTX levels at 24, 42 and 48 hours after HDMTX infusion. Severe renal dysfunction after HDMTX infusion in children with ALL is a very rare complication. HDMTX therapeutic procedures may have a high level of patient safety when exact consideration is given to support therapy. | |
| References | 1. Bertino J.R., Kamen B., Romanini A.: Folate antagonists. In: (Holland J.F., Frei E., Bast R.C., Kufe D.W., Morton D.C., Weichselbaum R.R., eds) Cance Medicine. Pp. 907-922, Williams and Wilkins, Baltimore
2. Crom W.R.: Methotrexate. In: (Grochow L.B., Ames M.M., eds) A Clinician’s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Pp. 311-330, Williams and Wilkins, Baltimore, 1998 3. Lawrenz-Wolf B., Wolfrom C., Frickel C., et al.: Severe renal impairment of methotrexate elimination after high-dose therapy. Clin. Padiatr. 206: 319-326 (1994) 4. Hempel L., Misselwitz J., Fleck C., et al.: Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med. Pediatr. Oncol. 40: 348-354 (2003) 5. Saland J.M., Leavy P.J., Bash R.O., et al.: Effective removal of methotrexate by high-flux hemodialysis. Pediatr. Nephrol. 17: 825-829 (2002) 6. Smeland E., Fuskevag O.M., Nymann K., et al.: High-dose 7-hydroxymethotrexate: Acute toxicity and lethality in a rat model. Cancer Chemother. Pharmacol. 37: 415-422 (1996) 7. Perazella M.A.: Crystal-induced acute renal failure. Am. J. Med. 106: 459-465 (1999) 8. Fuskevag O.M., Kristiansen C., Olsen R., et al.: Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate. Ultrastruct. Pathol. 24: 325-332 (2000) 9. Seidel H., Moe P.J., Nygaard R., et al.: Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr. Hematol. Oncol. 11: 165-172 (1994) 10. Skarby T., Jonsson P., Hjorth L., et al.: High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukemia (ALL). Cancer Chemother. Pharmacol. 35: 324-343 (2003) 11. Kamen B.: Folate and antifolate pharmacology. Semin. Oncol. 5(suppl 18): S30-S39 (1997) 12. Relling M.V., Fairclough D., Ayers D., et al.: Patients characteristics associated with high-risk methotrexate concentrations and toxicity. J. Clin. Oncol. 12: 1667-1672 (1994) 13. Joannon P., Oviedo I., Campbell M., Tordecilla J.: High- dose methotrexate therapy of childhood acute lymphoblastic leukaemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr. Blood Cancer 43: 17-22 (2004) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|